37 results
Thumbnail

D2.480 - Features of the molecular sensitization profile in children with autism spectrum disorder

Thumbnail

D2.485 - Comprehensive Understanding of the Characteristics of Pediatric Pollen Allergy Patients

Thumbnail

D2.486 - Levels of house dust mite in dust settlements are associated with risk for allergic rhinitis in children

Thumbnail

D2.489 - B-Cell Subset Reconstitution After Rituximab-Containing Chemotherapy in Children and Adolescents With Non-Hodgkin Lymphoma: A Single-Center Experience

Thumbnail

D2.478 - HEREDITORY ANGIOEDEMA - A case report

Thumbnail

D2.477 - Nationwide Survey of Healthcare Transition from Paediatric to Adult Services for Allergic Diseases in Japan

Thumbnail

D2.479 - The bullous pemphigoid in a baby

Thumbnail

D2.481 - Severe obstructive syndrome in children with bronchopulmonary malformations

Thumbnail

D2.482 - Neuroendocrine Cell Hyperplasia of Infancy (NEHI): Report of 7 Cases

Thumbnail

D2.483 - Outdoor Activity and Screen Time at Age 3 years and Allergic Symptoms at Age 6 years: A Nationwide Birth Cohort Study (JECS)

Thumbnail

D2.487 - Avoiding Unnecessary Food Avoidance: Outcomes of Infants with Localised Reactions During Weaning

Thumbnail

D2.488 - Functional confirmation of exercise-induced bronchoconstriction in children: A three-year retrospective study

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to